Home›Trial›NCT02937272
🔬NCT02937272Phase 1ACTIVE NOT RECRUITING

A Study of LY3200882 in Participants With Solid Tumors

Study Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Conditions
Solid Tumor
Interventions / Drugs
LY3200882LY3300054Gemcitabinenab-PaclitaxelCisplatinIntensity Modulated Radiotherapy
View on ClinicalTrials.gov ↗
Sponsor
LLY
Eli Lilly and Company
Diabetes/Oncology
C53/100
Study Details
Enrollment223 participants
Primary Completion—
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.866963+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.